Managers / Q3 2019 · view latest →
SV Health Investors, LLC
CIK 0001587143 · ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON, MA, 02108 · 617-367-8100
Summary
Sv Health Investors, LLC reported $142M in U.S.-listed holdings across 10 positions for Q3 2019.
The portfolio is heavily concentrated: Misonix alone accounts for 23.9% of reported value.
Compared with Q2 2019, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 59.0% · $84M
- Other · 25.7% · $37M
- ADR · 15.3% · $22M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MISONIX, INC. | NEW | +1.70M | 1.70M | +$34M | $34M |
| DECIPHERA PHARMACEUTICALS INC | TRIMMED | −376.2K | 542.1K | −$2M | $18M |
| AVROBIO INC | TRIMMED | −513.5K | 1.42M | −$11M | $20M |
| KALVISTA PHARMACEUTICALS INC | HELD | +0 | 1.72M | −$18M | $20M |
| TRANSENTERIX INC | HELD | +0 | 6.63M | −$5M | $4M |
| SUTRO BIOPHARMA INC | HELD | +0 | 1.82M | −$4M | $17M |
| BCYCBICYCLE THERAPEUTICS PLC | HELD | +0 | 1.92M | +$3M | $22M |
| OCULOCULAR THERAPEUTIX INC | HELD | +0 | 628.2K | −$854,000 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MISONIX, INC. | COM | 23.94% | $34M | 1.70M |
| 2 | BCYCBICYCLE THERAPEUTICS PLChistory → | SPONSORED ADS | 15.32% | $22M | 1.92M |
| 3 | AVROBIO INC | COM | 14.06% | $20M | 1.42M |
| 4 | KALVISTA PHARMACEUTICALS INC | COM | 14.01% | $20M | 1.72M |
| 5 | DECIPHERA PHARMACEUTICALS INC | COM | 12.92% | $18M | 542.1K |
| 6 | SUTRO BIOPHARMA INC | COM | 11.65% | $17M | 1.82M |
| 7 | TRANSENTERIX INC | COM NEW | 2.89% | $4M | 6.63M |
| 8 | X4 PHARMACEUTICALS INC | COM | 2.78% | $4M | 311.5K |
| 9 | OCULOCULAR THERAPEUTIX INChistory → | COM | 1.34% | $2M | 628.2K |
| 10 | CATABASIS PHARMACEUTICALS IN | COM NEW | 1.08% | $2M | 285.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $32M | 4 | Nov 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $44M | 5 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $83M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $155M | 6 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $204M | 8 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $230M | 7 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $267M | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $208M | 9 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $197M | 10 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $144M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $119M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $165M | 10 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 10 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $149M | 9 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $170M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $162M | 9 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 4 additional managers.
- SVLSF IV, LLC028-16272
- SV Life Sciences Fund IV (GP), L.P.028-16273
- SVLSF VI, LLC028-19256
- SV Life Sciences Fund VI (GP), L.P.028-19255
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.